Novo Nordisk A/S
Copenhagen : NOVO B

June 21, 2012 16:13 ET

Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue

BAGSVAERD, DENMARK--(Marketwire - Jun 21, 2012) -

Company announcement No 40 / 2012:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE [HUG#1621397]

Contact Information